GT201200339A - Compuestos, composiciones de tioacetato y mètodos de uso - Google Patents
Compuestos, composiciones de tioacetato y mètodos de usoInfo
- Publication number
- GT201200339A GT201200339A GT201200339A GT201200339A GT201200339A GT 201200339 A GT201200339 A GT 201200339A GT 201200339 A GT201200339 A GT 201200339A GT 201200339 A GT201200339 A GT 201200339A GT 201200339 A GT201200339 A GT 201200339A
- Authority
- GT
- Guatemala
- Prior art keywords
- methods
- compounds
- thioacetate
- compositions
- levels
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/62—Oxygen or sulfur atoms
- C07D213/70—Sulfur atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/443—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4433—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/38—One sulfur atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D241/18—Oxygen or sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Obesity (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pyridine Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
LA PRESENTE INVENCIÓN SE REFIERE A COMPUESTOS ÚTILES EN LA MODULACIÓN DE LOS NIVELES DE ÁCIDO ÚRICO EN SANGRE, FORMULACIONES QUE LOS CONTIENEN Y MÉTODOS DE USO DE ELLOS. EN ALGUNAS FORMAS DE REALIZACIÓN, LOS COMPUESTOS DESCRITOS EN EL PRESENTE DOCUMENTO SE UTILIZAN EN EL TRATAMIENTO O PREVENCIÓN DE TRASTORNOS RELACIONADOS CON LOS NIVELES ABERRANTES DE ÁCIDO ÚRICO.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US35549110P | 2010-06-16 | 2010-06-16 |
Publications (1)
Publication Number | Publication Date |
---|---|
GT201200339A true GT201200339A (es) | 2015-02-11 |
Family
ID=45348850
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
GT201200339A GT201200339A (es) | 2010-06-16 | 2012-12-13 | Compuestos, composiciones de tioacetato y mètodos de uso |
Country Status (41)
Families Citing this family (38)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2802692C (en) | 2010-06-16 | 2016-01-05 | Ardea Biosciences, Inc. | Phenylthioacetate compounds useful as uricosuric agents |
AR081930A1 (es) * | 2010-06-16 | 2012-10-31 | Ardea Biosciences Inc | Compuestos de tioacetato |
JP6025853B2 (ja) * | 2011-11-03 | 2016-11-16 | アルデア バイオサイエンシーズ インク. | 3,4−二置換ピリジン化合物、その使用方法、および、該化合物を含む組成物 |
WO2014077285A1 (ja) | 2012-11-14 | 2014-05-22 | 帝人ファーマ株式会社 | ピリジン誘導体 |
MX362747B (es) * | 2013-05-13 | 2019-02-05 | Shanghai hengrui pharmaceutical co ltd | Derivado de ácido cicloalquilo, método de preparación del mismo, y aplicación farmacéutica del mismo. |
WO2014209034A1 (en) * | 2013-06-27 | 2014-12-31 | Lg Life Sciences Ltd. | Biaryl derivatives as gpr120 agonists |
CN106458998A (zh) | 2014-05-13 | 2017-02-22 | 帝人制药株式会社 | 吡嗪衍生物 |
CN105439946B (zh) * | 2014-08-13 | 2018-02-02 | 益方生物科技(上海)有限公司 | 羧酸化合物及其制备方法和用途 |
CN107567443B (zh) * | 2014-12-24 | 2023-04-28 | 株式会社Lg化学 | 作为gpr120激动剂的联芳基衍生物 |
CN107108478B (zh) * | 2014-12-29 | 2020-04-24 | 日本化学药品株式会社 | Urat1抑制剂 |
CN108026043A (zh) * | 2015-08-14 | 2018-05-11 | 广东东阳光药业有限公司 | 一种萘环化合物的晶型 |
CN105418495B (zh) * | 2015-11-25 | 2018-09-14 | 乳源瑶族自治县大众药品贸易有限公司 | 一种硫醚的制备方法 |
JP6752888B2 (ja) * | 2015-12-07 | 2020-09-09 | ヒノバ ファーマシューティカルズ インコーポレイテッド | キノリン系化合物とその調製方法および尿酸トランスポータ阻害剤類薬物としての使用 |
CN108289848A (zh) * | 2015-12-08 | 2018-07-17 | 阿迪亚生命科学公司 | 包含urat1的有效抑制剂的药物组合物 |
JP6898330B2 (ja) * | 2015-12-28 | 2021-07-07 | シャンハイ フォチョン ファーマシューティカル カンパニー リミテッド | インドリジン誘導体、組成物、及び使用方法 |
WO2017121308A1 (en) * | 2016-01-11 | 2017-07-20 | Chongqing Fochon Pharmaceutical Co., Ltd. | Fused pyridine compounds, compositions and methods of use |
EP3416955B1 (en) * | 2016-02-15 | 2020-09-09 | Institut National de la Sante et de la Recherche Medicale (INSERM) | Use of stiripentol and their derivatives for decreasing urinary oxalate concentration in an individual |
CN105884807A (zh) * | 2016-04-26 | 2016-08-24 | 昆药集团股份有限公司 | 硼酸频那醇酯衍生物的制备方法、硫代乙酸盐化合物的制备方法 |
CN106117130A (zh) * | 2016-06-28 | 2016-11-16 | 昆药集团股份有限公司 | 一种2‑((3‑(4‑氰基萘‑1‑基)吡啶‑4‑基)硫基)‑2‑甲基丙酸的晶型及其制备方法和药物组合物 |
CN106083847B (zh) * | 2016-08-03 | 2018-10-30 | 山东大学 | 一种咪唑并吡啶巯乙酸类衍生物及其制备方法与应用 |
CN110121359A (zh) | 2016-11-11 | 2019-08-13 | 怀特黑德生物制剂研究所 | 人血浆培养基 |
CN106748987B (zh) * | 2016-11-18 | 2019-05-31 | 昆药集团股份有限公司 | 2-((3-(4-氰基萘-1-基)吡啶-4-基)硫基)-2-甲基丙酸钠盐的晶型 |
BR112019011211A2 (pt) | 2016-12-16 | 2019-10-15 | Basf Se | compostos de fórmula i, composição, métodos para combater ou controlar pragas invertebradas, para proteger plantas em crescimento de ataque ou infestação por pragas invertebradas, semente, uso de um composto e método para tratar ou proteger um animal |
CN106883169A (zh) * | 2017-04-01 | 2017-06-23 | 浙江永宁药业股份有限公司 | 一种3‑(4‑氰基‑1‑萘基)‑4‑卤代吡啶的制备方法及其应用 |
WO2018202039A1 (zh) * | 2017-05-03 | 2018-11-08 | 成都海创药业有限公司 | 杂环化合物及其制备方法 |
AU2018345221A1 (en) * | 2017-10-04 | 2020-05-07 | Japan Tobacco Inc. | Nitrogen-containing heteroaryl compound, and pharmaceutical use thereof |
CN107955029B (zh) * | 2017-12-07 | 2020-08-11 | 成都美域高制药有限公司 | 一种雷西纳德的制备方法 |
CN108084153A (zh) * | 2017-12-20 | 2018-05-29 | 广东赛烽医药科技有限公司 | 吡啶基硫代乙酸化合物、组合物及其应用 |
CN108069940B (zh) * | 2017-12-20 | 2021-04-30 | 广东赛烽医药科技有限公司 | 硫代乙酸化合物、组合物及其应用 |
CN108440397B (zh) * | 2018-03-06 | 2020-06-05 | 南方医科大学 | 3-(萘-1-甲基取代)吡啶衍生物及其合成方法和应用 |
WO2019183835A1 (en) | 2018-03-28 | 2019-10-03 | Inventisbio Shanghai Ltd. | Novel salt forms of urat-1 inhibitors |
CN109608432B (zh) * | 2018-12-17 | 2022-10-11 | 江苏艾立康医药科技有限公司 | 作为urat1抑制剂的噻吩类衍生物 |
WO2021009197A1 (en) | 2019-07-16 | 2021-01-21 | Astrazeneca Ab | Dose dumping resistant pharmaceutical compositions comrising verinurad |
CN114315715B (zh) * | 2020-09-29 | 2024-02-20 | 杭州中美华东制药有限公司 | 一类urat1抑制剂及其制备方法与应用 |
CN114621136B (zh) * | 2020-12-09 | 2023-11-07 | 江苏正大清江制药有限公司 | 吡啶巯乙酸类化合物及其制备方法、药学衍生物或配剂以及应用 |
CN115385854B (zh) * | 2021-05-19 | 2024-04-09 | 江苏正大清江制药有限公司 | 一种喹啉巯乙酸磺酰胺类衍生物的制备及其应用 |
CN113979931B (zh) * | 2021-10-08 | 2023-06-13 | 南方医科大学 | 一种吡啶3-胺衍生物及其制备方法和应用 |
CN114214361A (zh) * | 2022-01-07 | 2022-03-22 | 中国农业科学院兰州兽医研究所 | 一种urat1人源化小鼠模型的构建方法及其应用 |
Family Cites Families (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BE642046A (es) * | 1963-01-03 | |||
ES475100A1 (es) * | 1977-11-21 | 1979-12-01 | Hoechst Ag | Un metodo para preparar acidos 1,2-benzisoxazoloxiaceticos |
JPS6054310B2 (ja) | 1979-02-21 | 1985-11-29 | 三井東圧化学株式会社 | ピリダジン誘導体と農園芸用殺菌剤 |
US4889868A (en) | 1984-12-20 | 1989-12-26 | Rorer Pharmaceutical Corporation | Bis-imidazolinoamino derivatives as antiallergy compounds |
US5051442A (en) | 1990-04-25 | 1991-09-24 | Merrell Dow Pharmaceuticals Inc. | 3-indolyl thioacetate derivatives and NMDA receptor antagonistic use thereof |
KR100221041B1 (ko) | 1990-11-30 | 1999-09-15 | 야스이 쇼사꾸 | 2-아릴티아졸 유도체 및 그의 약제학적 조성물 |
JPH06234732A (ja) * | 1992-09-10 | 1994-08-23 | Banyu Pharmaceut Co Ltd | 置換アセトアミド誘導体 |
CA2105617A1 (en) | 1992-09-10 | 1994-03-11 | Yoshikazu Iwasawa | Substituted acetamide derivatives |
US5344651A (en) | 1993-07-23 | 1994-09-06 | The Procter & Gamble Company | Cyproterone acetate thioacetate |
US5580979A (en) | 1994-03-15 | 1996-12-03 | Trustees Of Tufts University | Phosphotyrosine peptidomimetics for inhibiting SH2 domain interactions |
WO1995029897A1 (en) | 1994-04-29 | 1995-11-09 | G.D. Searle & Co. | METHOD OF USING (H+/K+) ATPase INHIBITORS AS ANTIVIRAL AGENTS |
US6017925A (en) | 1997-01-17 | 2000-01-25 | Merck & Co., Inc. | Integrin antagonists |
ES2339738T3 (es) * | 1999-01-22 | 2010-05-25 | Elan Pharmaceuticals, Inc. | Derivados de acilo los cuales tratan trastornos relacionados con vla-4. |
GB0108339D0 (en) | 2001-04-03 | 2001-05-23 | Syngenta Participations Ag | Organics compounds |
WO2007050087A1 (en) | 2004-08-25 | 2007-05-03 | Ardea Biosciences, Inc. | N[S(4-aryl-triazol-3-yl)α -mercaptoacetyl]-p-amino benozoic acids AS HIV REVERSE TRANSCRIPTASE INHIBITORS |
SG155246A1 (en) | 2004-08-25 | 2009-09-30 | Ardea Biosciences Inc | S-TRIAZOLYL α-MERCAPTOACETANILIDES AS INHIBITORS OF HIV REVERSE TRANSCRIPTASE |
GB0422057D0 (en) | 2004-10-05 | 2004-11-03 | Astrazeneca Ab | Novel compounds |
US20070135437A1 (en) * | 2005-03-04 | 2007-06-14 | Alsgen, Inc. | Modulation of neurodegenerative diseases |
WO2006138118A2 (en) | 2005-06-15 | 2006-12-28 | New York Blood Center | Anti-viral compositions comprising heterocyclic substituted phenyl furans and related compounds |
US20070099970A1 (en) * | 2005-08-19 | 2007-05-03 | Mackerell Alexander | Immunomodulatory compounds that target and inhibit the pY'binding site of tyrosene kinase p56 LCK SH2 domain |
EP2001897A2 (en) | 2006-03-22 | 2008-12-17 | Syndexa Pharmaceuticals Corporation | Compounds and methods for treatment of disorders associated with er stress |
AU2007292816B2 (en) | 2006-09-07 | 2011-11-17 | Amgen Inc. | Benzo-fused compounds for use in treating metabolic disorders |
EP1939181A1 (en) | 2006-12-27 | 2008-07-02 | sanofi-aventis | Heteroaryl-substituted carboxamides and use thereof for the stimulation of the expression of NO synthase |
ES2431815T3 (es) * | 2007-04-11 | 2013-11-28 | Kissei Pharmaceutical Co., Ltd. | Derivado de (aza)indol y uso del mismo para fines médicos |
TWI415840B (zh) * | 2007-11-27 | 2013-11-21 | Ardea Biosciences Inc | 新穎化合物、組合物及使用方法 |
US8173690B2 (en) * | 2008-09-04 | 2012-05-08 | Ardea Biosciences, Inc. | Compounds, compositions and methods of using same for modulating uric acid levels |
JP2012502050A (ja) | 2008-09-04 | 2012-01-26 | アルディア バイオサイエンス,インク. | 尿酸値を調節するための化合物、組成物及びそれを使用する方法。 |
WO2010048592A1 (en) | 2008-10-24 | 2010-04-29 | Ardea Biosciences, Inc. | Compositions comprising 4- (2- ( 5-br0m0-4- ( 1-cyclopropylnaphthalen-4-yl) -4h-1, 2, 4-triaz0l-3-ylthi0) acetamido -3-chlorobenzoic acid and pharmaceutically acceptable salts thereof |
US20120122780A1 (en) | 2009-05-20 | 2012-05-17 | Ardea Biosciences Inc. | Compounds, Compositions and Methods for Modulating Uric Acid Levels |
WO2010135536A2 (en) | 2009-05-20 | 2010-11-25 | Ardea Biosciences, Inc. | Methods of modulating uric acid levels |
WO2011044140A1 (en) | 2009-10-05 | 2011-04-14 | Catabasis Pharmaceuticals, Inc. | Substituted thioacetic acid salicylate derivatives and their uses |
CA2802692C (en) * | 2010-06-16 | 2016-01-05 | Ardea Biosciences, Inc. | Phenylthioacetate compounds useful as uricosuric agents |
AR081930A1 (es) | 2010-06-16 | 2012-10-31 | Ardea Biosciences Inc | Compuestos de tioacetato |
JP6025853B2 (ja) * | 2011-11-03 | 2016-11-16 | アルデア バイオサイエンシーズ インク. | 3,4−二置換ピリジン化合物、その使用方法、および、該化合物を含む組成物 |
-
2011
- 2011-06-14 AR ARP110102068A patent/AR081930A1/es active IP Right Grant
- 2011-06-15 SI SI201130149T patent/SI2585437T1/sl unknown
- 2011-06-15 PL PL15166826T patent/PL2975025T3/pl unknown
- 2011-06-15 UA UAA201300527A patent/UA107115C2/ru unknown
- 2011-06-15 ME MEP-2015-173A patent/ME02302B/me unknown
- 2011-06-15 MX MX2012014863A patent/MX2012014863A/es active IP Right Grant
- 2011-06-15 HU HUE13198843A patent/HUE025962T2/en unknown
- 2011-06-15 CA CA2802535A patent/CA2802535C/en active Active
- 2011-06-15 PT PT151668266T patent/PT2975025T/pt unknown
- 2011-06-15 CU CU20120170A patent/CU24126B1/es active IP Right Grant
- 2011-06-15 HU HUE15166826A patent/HUE040209T2/hu unknown
- 2011-06-15 AU AU2011268360A patent/AU2011268360B2/en active Active
- 2011-06-15 MY MYPI2012005401 patent/MY153039A/en unknown
- 2011-06-15 EP EP13198843.8A patent/EP2712861B1/en active Active
- 2011-06-15 EP EP15166826.6A patent/EP2975025B1/en active Active
- 2011-06-15 PL PL11796396T patent/PL2585437T3/pl unknown
- 2011-06-15 MX MX2014004120A patent/MX343583B/es unknown
- 2011-06-15 US US13/703,890 patent/US10266493B2/en active Active
- 2011-06-15 EP EP18159710.5A patent/EP3409661A1/en not_active Withdrawn
- 2011-06-15 EP EP11796396.7A patent/EP2585437B1/en active Active
- 2011-06-15 SI SI201131491T patent/SI2975025T1/en unknown
- 2011-06-15 CN CN201180029484.7A patent/CN103068801B/zh active Active
- 2011-06-15 KR KR1020147006531A patent/KR101608604B1/ko active IP Right Grant
- 2011-06-15 EP EP19178229.1A patent/EP3611167A1/en active Pending
- 2011-06-15 BR BR112012032028-9A patent/BR112012032028B1/pt active IP Right Grant
- 2011-06-15 WO PCT/US2011/040585 patent/WO2011159839A2/en active Application Filing
- 2011-06-15 ES ES15166826.6T patent/ES2673426T3/es active Active
- 2011-06-15 PE PE2012002423A patent/PE20131047A1/es active IP Right Grant
- 2011-06-15 ES ES13198843.8T patent/ES2551114T3/es active Active
- 2011-06-15 DK DK13198843.8T patent/DK2712861T3/en active
- 2011-06-15 SG SG2012091195A patent/SG186298A1/en unknown
- 2011-06-15 TW TW103135886A patent/TWI501949B/zh active
- 2011-06-15 LT LTEP15166826.6T patent/LT2975025T/lt unknown
- 2011-06-15 PT PT117963967T patent/PT2585437E/pt unknown
- 2011-06-15 TW TW100120935A patent/TWI460173B/zh active
- 2011-06-15 RS RS20180652A patent/RS57363B1/sr unknown
- 2011-06-15 RS RS20140227A patent/RS53301B/en unknown
- 2011-06-15 KR KR1020137000923A patent/KR101432950B1/ko active IP Right Grant
- 2011-06-15 SI SI201130639T patent/SI2712861T1/sl unknown
- 2011-06-15 PL PL13198843T patent/PL2712861T3/pl unknown
- 2011-06-15 ME MEP-2014-42A patent/ME01830B/me unknown
- 2011-06-15 RS RS20150668A patent/RS54375B1/en unknown
- 2011-06-15 JP JP2013515492A patent/JP5551310B2/ja active Active
- 2011-06-15 ES ES11796396.7T patent/ES2459146T3/es active Active
- 2011-06-15 CN CN201410141662.0A patent/CN103864677B/zh active Active
- 2011-06-15 PT PT131988438T patent/PT2712861E/pt unknown
- 2011-06-15 TR TR2018/08344T patent/TR201808344T4/tr unknown
- 2011-06-15 DK DK11796396.7T patent/DK2585437T3/da active
- 2011-06-15 EA EA201270803A patent/EA022933B1/ru unknown
- 2011-06-15 DK DK15166826.6T patent/DK2975025T3/en active
- 2011-06-15 SG SG10201702527TA patent/SG10201702527TA/en unknown
-
2012
- 2012-12-04 IL IL223435A patent/IL223435A/en active IP Right Grant
- 2012-12-13 GT GT201200339A patent/GT201200339A/es unknown
- 2012-12-13 HN HN2012002664A patent/HN2012002664A/es unknown
- 2012-12-14 CL CL2012003546A patent/CL2012003546A1/es unknown
- 2012-12-14 DO DO2012000314A patent/DOP2012000314A/es unknown
- 2012-12-17 CO CO12228040A patent/CO6640311A2/es active IP Right Grant
- 2012-12-18 CR CR20120649A patent/CR20120649A/es unknown
- 2012-12-18 ZA ZA2012/09574A patent/ZA201209574B/en unknown
- 2012-12-20 EC ECSP12012353 patent/ECSP12012353A/es unknown
-
2013
- 2013-04-04 US US13/857,108 patent/US8541589B2/en active Active
- 2013-06-07 US US13/913,272 patent/US8629278B2/en active Active
- 2013-06-28 HK HK13107640.4A patent/HK1180327A1/xx unknown
-
2014
- 2014-04-24 SM SM201400055T patent/SMT201400055B/xx unknown
- 2014-04-29 HR HRP20140391AT patent/HRP20140391T1/hr unknown
- 2014-05-21 JP JP2014105611A patent/JP5768166B2/ja active Active
- 2014-12-03 IL IL236039A patent/IL236039A0/en active IP Right Grant
-
2015
- 2015-06-15 JP JP2015120633A patent/JP6112318B2/ja active Active
- 2015-10-19 HR HRP20151105TT patent/HRP20151105T1/hr unknown
- 2015-10-22 SM SM201500260T patent/SMT201500260B/it unknown
-
2016
- 2016-06-21 HK HK16107170.9A patent/HK1219102A1/zh unknown
-
2017
- 2017-02-27 JP JP2017035549A patent/JP6364515B2/ja active Active
-
2018
- 2018-05-25 HR HRP20180829TT patent/HRP20180829T1/hr unknown
- 2018-06-27 CY CY20181100629T patent/CY1120337T1/el unknown
- 2018-06-28 JP JP2018123691A patent/JP2018168174A/ja active Pending
- 2018-11-14 US US16/190,925 patent/US10919858B2/en active Active
-
2020
- 2020-12-16 US US17/123,380 patent/US20210171466A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
GT201200339A (es) | Compuestos, composiciones de tioacetato y mètodos de uso | |
ECSP10010310A (es) | Nuevos compuestos y composiciones y métodos de uso | |
CO7121325A2 (es) | Nuevos diazaespirocicloalcanos y azaespirocicloalcanos | |
CY1118680T1 (el) | Φαρμακευτικη συνθεση | |
CL2013002517A1 (es) | Compuestos derivados de fosforoamidato de 5-fluoro-2'-desoxiuridina; procedimiento de preparacion; composicion farmaceutica que los comprende; su uso en el tratamiento o profilaxis del cancer. | |
EA201490922A1 (ru) | ПРОИЗВОДНЫЕ ГИДАНТОИНА, ПОЛЕЗНЫЕ В КАЧЕСТВЕ ИНГИБИТОРОВ Kv3-КАНАЛОВ | |
UY35427A (es) | Compuestos y sus usos en la modulación de la hemoglobina | |
EA201491505A1 (ru) | Соединения для лечения спинальной мышечной атрофии | |
UY35472A (es) | Compuestos y sus usos en la modulacion de la hemoglobina | |
CO6680675A2 (es) | Tidiazoles substituidos y composiciones pesticidas que los contienen | |
UY35426A (es) | Compuestos y sus usos en la modulación de la hemoglobina | |
BR112012032193A2 (pt) | composto, composiçoes e métodos de uso de feniltioacetato | |
AR090465A1 (es) | Formas solidas de un profarmaco de nucleotidos de tiofosforamidato | |
SV2009003392A (es) | Aril pirrolidinas insecticidas | |
EA201270257A1 (ru) | Производные n1-сульфонил-5-фторпиримидинона | |
CO7160059A2 (es) | Formulación líquida | |
GT201200165A (es) | Triazolopiridinas | |
CR11548A (es) | Azolilmetiloxiranos, su uso y agentes que los contienen | |
EA201491766A1 (ru) | Соединения для лечения спинальной мышечной атрофии | |
EA201992707A1 (ru) | Соединения и их применения для модуляции гемоглобина | |
CO2017004735A2 (es) | Moléculas que tienen utilidad plaguicida e intermediarios, composiciones y procedimientos relacionados con las mismas | |
CO2017000220A2 (es) | Moléculas que tienen cierta utilidad pesticida, intermedios, composiciones y procesos relacionados con las mismas | |
UY29417A1 (es) | Agentes endoparasiticidas | |
PA8797801A1 (es) | Uso de n-fenilamidas de acido 2-sulfonilaminobenzoico sustituidas con sulfonilo en el tratamiento del dolor | |
WO2014194053A3 (en) | Carbohydrate compounds for nutritional and therapeutic use |